HC Wainwright Reiterates Buy Rating for Coya Therapeutics (NASDAQ:COYA)

Coya Therapeutics (NASDAQ:COYA)‘s stock had its “buy” rating reiterated by equities research analysts at HC Wainwright in a research report issued to clients and investors on Monday,Benzinga reports. They currently have a $18.00 price objective on the stock. HC Wainwright’s target price would indicate a potential upside of 327.55% from the stock’s current price.

COYA has been the subject of a number of other research reports. Chardan Capital reiterated a “buy” rating and issued a $14.00 target price on shares of Coya Therapeutics in a report on Monday, March 16th. Wall Street Zen downgraded Coya Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday. Weiss Ratings reiterated a “sell (d-)” rating on shares of Coya Therapeutics in a research report on Wednesday, January 21st. Finally, D. Boral Capital reissued a “buy” rating and issued a $15.00 target price on shares of Coya Therapeutics in a research note on Monday, March 16th. Five equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Coya Therapeutics currently has a consensus rating of “Moderate Buy” and an average price target of $16.00.

Coya Therapeutics Stock Down 1.4%

Coya Therapeutics stock opened at $4.21 on Monday. The company’s 50-day moving average price is $4.69 and its 200-day moving average price is $5.51. The company has a market cap of $98.75 million, a PE ratio of -3.31 and a beta of 0.23. Coya Therapeutics has a twelve month low of $3.94 and a twelve month high of $7.75.

Coya Therapeutics (NASDAQ:COYA) last released its quarterly earnings results on Monday, March 16th. The company reported ($0.34) EPS for the quarter, missing the consensus estimate of ($0.08) by ($0.26). Coya Therapeutics had a negative return on equity of 62.76% and a negative net margin of 267.13%.The company had revenue of $3.96 million during the quarter, compared to analysts’ expectations of $1.93 million. As a group, sell-side analysts expect that Coya Therapeutics will post -1.15 earnings per share for the current fiscal year.

Institutional Trading of Coya Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in the company. JPMorgan Chase & Co. bought a new position in Coya Therapeutics during the 3rd quarter worth about $28,000. CIBC Private Wealth Group LLC bought a new stake in shares of Coya Therapeutics in the 4th quarter valued at about $47,000. Occudo Quantitative Strategies LP purchased a new stake in shares of Coya Therapeutics in the 4th quarter worth approximately $66,000. Lantern Wealth Advisors LLC purchased a new stake in shares of Coya Therapeutics in the 3rd quarter worth approximately $66,000. Finally, Oppenheimer & Co. Inc. bought a new position in shares of Coya Therapeutics during the fourth quarter valued at approximately $81,000. 39.75% of the stock is currently owned by institutional investors.

Coya Therapeutics Company Profile

Coya Therapeutics, Inc (NASDAQ: COYA) is a clinical‐stage biotechnology company focused on the discovery and development of first‐in‐class therapeutics for fibrotic diseases and cancer. The company’s scientific approach centers on targeting UNC-45A, a molecular chaperone implicated in the regulation of cell motility, proliferation and extracellular matrix deposition. By modulating the activity of UNC-45A, Coya aims to address underlying mechanisms of tissue fibrosis and tumor progression that currently lack effective treatments.

Coya’s pipeline is anchored by two lead programs: COY-001, a small‐molecule inhibitor in preclinical development for fibrotic disorders such as idiopathic pulmonary fibrosis and systemic sclerosis, and COY-002, which is being advanced toward the clinic for certain solid tumors.